Abbott has received an FDA clearance for the latest version of its sensor-laden catheter used to map out the electrical ...

Capricor Therapeutics is taking a victory lap for their phase 2 Duchenne muscular dystrophy (DMD) trial. | Capricor ...

In a year that has seen an approval and a raft of readouts for metabolic dysfunction-associated steatohepatitis (MASH), ...

Upstream Bio has swollen its IPO to $255 million as the company joins CAMP4 Therapeutics this morning in becoming the latest ...

In order to focus its resources on the phase 1 program, dubbed TIDAL-01, the company has today announced a reduction in staff ...

Difficult. Impossible. Agonizing. Worse than voting in the national election. | Difficult. Impossible. Agonizing. Worse than ...

Alaunos Therapeutics is axing an agreement with Precigen, giving up licensing rights to a personalized T-cell platform. | ...

Sanofi has stopped a phase 2 trial of Denali Therapeutics-partnered oditras | Sanofi has stopped a phase 2 trial of the ...

Bruker has formed a new, single division out of the various spatial biology assets it has acquired over the years. | Bruker ...

Eli Lilly is ramping up its efforts to incorporate AI across its business by appointing Thomas Fuchs to the new role of chief ...

Immatics has vaulted into phase 3 on the strength of early-stage data. The biotech is gearing up to start a pivotal trial of ...

Booster Therapeutics has launched with $15 million in seed financing and a mission to take on the current crop of targeted ...